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Abstract The aims of this study were twofold. The first was
to investigate the diagnostic performance of two biochemical
markers, procalcitonin (PCT) and lipopolysaccharide-binding
protein (LBP), considering each individually and then com-
bined, for the postmortem diagnosis of sepsis. We also tested
the usefulness of pericardial fluid for postmortem LBP deter-
mination. Two study groups were formed, a sepsis-related
fatalities group of 12 cases and a control group of 30 cases.
Postmortem native CT scans, autopsy, histology, neuropathol-
ogy, and toxicology as well as other postmortem biochemical
investigations were performed in all cases. Microbiological
investigations were also carried out in the septic group. Post-
mortem serum PCT and LBP levels differed between the two
groups. Both biomarkers, individually considered, allowed
septic states to be diagnosed, whereas increases in both post-
mortem serum PCT and LBP levels were only observed in
cases of sepsis. Similarly, normal PCT and LBP values in
postmortem serum were identified only in non-septic cases.
Pericardial fluid LBP levels do not correlate with the presence
of underlying septic states. No relationship was observed
between postmortem serum and pericardial fluid LBP levels
in either septic or non-septic groups, or between pericardial
fluid PCT and LBP levels.
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Introduction
Reliable diagnosis of sepsis remains a major challenge for
forensic pathologists despite extensive research and devel-
opment in immunohistochemistry and postmortem bio-
chemistry. Medical records are often unavailable when
autopsy is performed, and macroscopic and microscopic
data may be elusive. Much effort has therefore been directed
toward identifying clinical biochemical parameters whose
measurements in the forensic casework might provide addi-
tional information and represent a reliable tool for estimat-
ing the probability of sepsis as cause of death. Biochemical
markers of inflammation and sepsis have mainly been tested
in postmortem serum from femoral blood and experimental-
ly measured in other biological substrates, such as pericar-
dial fluid [1], vitreous humor, cerebrospinal fluid [2], and
liver [3], at times with promising results.
Several investigations in living people have confirmed
the usefulness of C-reactive protein (CRP) and procalcitonin
(PCT) as biochemical markers for the diagnosis of systemic
inflammation and bacterial sepsis. In the forensic field, these
parameters can easily be measured in peripheral and cardiac
blood as well as in postmortem serum. Furthermore, they
may be used for forensic purposes as in clinical practice.
Nevertheless, the diagnostic power of these markers in
detecting sepsis-related fatalities is somehow unsatisfactory.
Indeed, some clinical studies have positively evaluated high
plasma CRP levels in patients with infection and sepsis,
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whereas results from many other studies have failed to show
the impact of elevated CRP levels for either the diagnosis of
infection and sepsis or the assessment of sepsis severity [4, 5].
CRP plasma levels may furthermore remain elevated several
days after elimination of the infectious focus and increased
levels have been described in many noninfectious conditions,
such as autoimmune and rheumatic disorders, acute coronary
syndromes, and malignant tumors post-surgery [5–8].
PCT elevation may already be recognized just 2 h after
endotoxemia or bacteremia [9, 10]. Nevertheless, as with
CRP, there are a number of noninfectious causes that may
result in increased PCT levels apart from bacterial infec-
tions, such as major surgery, severe trauma, exertional heat
stroke, or burns [11–15]. Plasma concentrations observed
under these conditions are not as high, however, as in
patients with severe sepsis or septic shock [5]. Increased
PCT values have also been described, together with other
signs of systemic inflammation, in prolonged cardiogenic
shock, likely in relation to endotoxin translocation after
gastrointestinal perfusion impairment [16, 17].
Lipopolysaccharide (LPS)-binding protein (LBP) was ini-
tially discovered by Tobias in 1986 as an acute-phase reactant
binding the LPS of Gram-negative bacteria wall to form LPS-
LBP complexes [18, 19]. Biochemically, LBP is a 50-kDa
polypeptide,mainly synthesized in the hepatocytes and released
into the bloodstream as a 58–60-kDa glycoprotein resulting
from glycosylation. The human form consists of 452 amino
acid residues in the mature protein with the typical 25-amino-
acid signal sequence that characterizes secreted proteins.
LBP is constitutively present in serum at concentrations
of 2–10 μg/ml. Levels may increase during the acute-phase
reaction [20] to reach peaks of up to 200 μg/ml [21].
Elevated LBP plasma levels have been described in early-
onset neonatal sepsis [22, 23] and in adults after extensive
cardiothoracic surgical procedures [24, 25]. A clinical study
performed by Meynaar et al. [24] concluded that PCT levels
were more helpful than LBP values in differentiating sepsis
from systemic inflammatory response syndrome (SIRS) in
critically ill patients admitted to hospital.
In the field of forensic pathology, Reichelt et al. [25]
monitored the postmortem course of three endogenous bio-
markers, including LBP, in a series of sepsis-related fatalities
and non-septic control individuals during the early postmor-
tem period. They concluded that LBP levels higher than
10 μg/ml in peripheral and venous blood could be regarded
as diagnostic hints for underlying sepsis in the deceased. This
appeared especially significant when at least two measure-
ments were performed at different postmortem times in order
to estimate the most probable LBP level at death.
In the study herein presented, PCT and LBP levels were
measured in postmortem serum from femoral blood and
pericardial fluid in a series of sepsis-related fatalities and
control individuals. The first objective of this study was to
assess the diagnostic performance of both parameters, com-
bined or individually considered, to detect sepsis-related
fatalities. The second aim was to compare pericardial fluid
to postmortem serum LBP levels to test the usefulness of
pericardial fluid for biochemical investigations. Postmortem
native CT scans, autopsy, histology, neuropathology, and
toxicology as well as other postmortem biochemical analy-
ses were performed in all cases selected for this study.
Material and methods
Subjects
Two study groups were formed: a sepsis-related fatalities group
and a control group. The sepsis-related fatalities group con-
sisted of 12 forensic autopsy cases (six males, six females, no
children) with a mean age of 52.7 years (range 17–80 years).
None of the subjects included in this group had a
documented diagnosis of sepsis in vivo and none had
been admitted to the hospital prior to death. Medical
records obtained prior to autopsies were consistent with
the hypothesis that underlying bacterial sepsis might be
at the origin of or contributing to death. Autopsies were
ordered by the public prosecutor due to the unclear
circumstances of death and the bodies were transferred
to the medicolegal center.
For all cases included in this group, complete forensic
autopsies were performed within 5–62 h after death (mean
postmortem period 22.6 h), always preceded by native CT
scans. Histology, neuropathology, and toxicology were per-
formed in all cases as well as microbiological investigations
on right cardiac blood.
Postmortem biochemical investigations were carried out
on postmortem serum from femoral blood (procalcitonin,
CRP, LBP, troponin I, NT-proBNP, tryptase, urea nitrogen,
creatinine, and uric acid), whole blood (3-beta-hydroxybu-
tyrate), vitreous humor (glucose, sodium, chloride), and
pericardial fluid (procalcitonin, LBP).
The cause of death was attributed to multiple organ
failure based on the results of postmortem investigations
as well as the exclusion of other causes of death. Underlying
bacterial septic states were postulated to be at the origin of
the multiple organ failures. Descriptive characteristics of the
investigated subjects and main postmortem investigation
findings are reported in Table 1.
The control group consisted of 30 forensic autopsy cases.
None of the subjects included in this group had a documented,
clinical diagnosis of sepsis in vivo and none had been admitted
to the hospital prior to death. Complete forensic autopsies were
performed between 8 and 51 h after death (mean 24.4 h), always
preceded by native CT scans. Histology, neuropathology, and
toxicology were performed in all cases, as well as biochemical
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analyses on postmortem serum from femoral blood, whole
blood, pericardial fluid, and vitreous humor. Microbiology was
not performed in any of the cases in this group.
Causes of death were determined to be drug intoxication
(eight cases), drowning (two cases), positional asphyxia
(one case), trauma post-traffic accident (five cases), stab
wounds (four cases), gunshot wounds (five cases), and
natural cardiac death (five cases).
Postmortem investigations failed to reveal findings con-
sistent with the existence of underlying bacterial infections
or septic states. Descriptive characteristics of the control
group subjects, main postmortem investigation findings,
and causes of death are reported in Table 2.
Sample collection
Femoral blood and postmortem serum from femoral blood
Using a sterile needle and syringe, postmortem blood sam-
ples were collected by aspiration through the femoral vein
during the autopsy. Part of the sample was centrifuged
immediately post-collection at 3,000×g for 15 min. After
centrifugation, the separated supernatant (postmortem se-
rum) was collected, stored in preservative-free tubes, and
frozen at −20 °C until analysis.
Right cardiac blood
The external side of the right atrium was sterilized by sear-
ing with a flamed scalpel blade. The cardiac blood was
aspired with a syringe and stored in blood culture bottles
(aerobic and anaerobic). The collected samples were imme-
diately incubated at 37 °C.
Pericardial fluid
Undiluted samples of pericardial fluid were collected
immediately post-pericardium incision during autopsy.
All samples were immediately centrifuged at 3,000×g
for 15 min. After centrifugation, the separated supernatant
Table 1 Summarizes the characteristics of the investigated subjects (septic cases, n012, six males, six females, mean age 52.7), laboratory results,
and main postmortem investigation findings
Subject and
postmortem
interval
Age Gender Postmortem serum
procalcitonin
Pericardial fluid
procalcitonin
Postmortem
serum LBP
Pericardial
fluid LBP
Microbiology
findings
Main postmortem
investigation findings
and medical records
1 46 F 23.37 13.84 6.1 6.0 m.b. Peritonitis
25 h
2 70 M 2.62 2.34 16.2 5.8 P. aeruginosa Necrotizing myocarditis
34 h Fibrinous pericarditis
Pneumonia
3 48 F 13.50 9.24 37.7 4.4 E. coli Pyelonephritis
15 h
4 49 M 0.06 0.06 15.4 6.0 m.b. Pneumonia
14 h Antibiotic treatment
5 80 F 2.76 2.30 70.1 10.2 E. coli Pneumonia
14 h
6 57 F 155.70 80.15 68.7 9.5 m.b. Abdominal infection
5 h
7 63 F 13.62 10.5 29.4 4.6 m.b. Peritonitis
62 h
8 74 F 2.31 1.75 19.8 6.7 m.b. Alzheimer
21 h Broncho-aspiration
Pneumonia
9 17 M 3.68 5.40 25.5 5.9 E. coli Pneumonia
12 h
10 45 M 47.34 45.75 30.08 8.1 E. coli Necrotizing fasciitis
27 h
11 39 M 12.34 1.81 24.2 11.4 n.i. Abdominal and pelvic
infection18 h
12 44 M 7.55 3.65 31.3 8.1 K. pneumoniae Pneumonia
24 h
n.i. not clearly identifiable pathogens, m.b. multiple bacteria
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Table 2 Summarizes the characteristics of the investigated subjects (control individuals, n030, 15 males and 15 females, mean age 39.2),
laboratory results, main postmortem investigation findings, and causes of death
Subject and
postmortem interval
Age Gender Postmortem serum
procalcitonin
Pericardial fluid
procalcitonin
Postmortem
serum LBP
Pericardial
fluid LBP
Main postmortem
investigation findings
1 18 F 0.06 0.06 2.1 2.0 Trauma (traffic accident)
19 h
2 32 M 0.06 0.06 5.2 3.9 Trauma (traffic accident)
26 h
3 50 F 0.06 0.06 4.1 3.7 Gunshot wounds
15 h
4 25 M 0.06 0.06 3.9 3.5 Stab wounds
21 h
5 20 F 0.06 0.06 8.1 5.6 Stab wounds
23 h
6 69 M 0.06 0.06 3.2 3.0 Natural death (cardiac)
39 h
7 71 F 0.06 0.06 2.2 2.1 Natural death (cardiac)
51 h
8 44 M 0.06 0.06 7.0 3.5 Trauma (traffic accident)
8 h
9 22 F 0.06 0.06 4.7 3.2 Trauma (traffic accident)
14 h
10 38 M 0.06 0.06 2.8 2.4 Trauma (traffic accident)
19 h
11 70 F 0.06 0.06 6.9 5.1 Natural death (cardiac)
23 h
12 30 M 0.06 0.06 3.3 2.5 Drug intoxication
39 h
13 29 F 0.06 0.06 5.6 4.4 Stab wounds
11 h
14 21 M 0.06 0.06 5.3 4.2 Stab wounds
16 h
15 35 F 0.06 0.06 8.5 7.7 Drug intoxication
27 h
16 37 M 0.06 0.06 4.4 3.2 Gunshot wounds
24 h
17 19 F 0.06 0.06 6.3 4.9 Drug intoxication
20 h
18 30 M 0.06 0.06 6.5 5.5 Gunshot wounds
21 h
19 32 F 0.06 0.06 7.4 6.2 Gunshot wounds
18 h
20 69 M 0.06 0.06 4.5 4.4 Natural death (cardiac)
31 h
21 43 F 0.06 0.06 7.0 3.5 Drug intoxication
32 h
22 21 M 0.06 0.06 5.8 3.8 Drug intoxication
16 h
23 36 F 0.06 0.06 8.4 17.9 Gunshot wounds
23 h
24 68 M 0.06 0.06 3.7 2.9 Natural death (cardiac)
20 h
25 23 F 0.06 0.06 6.5 5.4 Drug intoxication
24 h
26 39 F 0.06 0.06 7.6 6.8 Drowning
33 h
27 41 F 0.06 0.06 2.6 12.2 Drug intoxication
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was collected, stored in preservative-free tubes, and frozen
at −20 °C until analysis.
Laboratory assays
Determination of procalcitonin concentration
PCTwas measured with the commercially available immuno-
assays on the Roche Modular E170 analyzer (Roche Diag-
nostic, Mannheim, Germany). The results were expressed in
micrograms per liter. The analytical sensitivity for PCT was
0.1 μg/l, according to manufacturer information.
Determination of LBP concentration
LBP was determined by chemiluminescent immunometric
assay Immulite®2000 (Siemens Medical, Germany). The
results were expressed in micrograms per milliliter. The
analytical sensitivity for LBP was 0.2 μg/ml, according to
manufacturer information.
Other analyses
Other biochemical analyses were performed according to
the laboratory standards and internal quality control
protocols.
Ethical considerations
All cases collected for this study underwent medicolegal
autopsies requested by the public prosecutor. Biochemical
analyses, including PCT, CRP, and LBP determinations,
were performed as part of the medicolegal investigations
and no further ethical permission was required to perform
laboratory analyses.
Statistical analyses
The data were analyzed by using STATA statistical software
package (STATA Corporation, College Station, TX, USA).
Receiver operator characteristic (ROC) curves, sensitivity,
and specificity values were calculated to assess the perfor-
mance of the selected biomarkers as diagnostic markers for
sepsis. Diagnostic accuracy was determined by the area
under the curves (AUC) of the studied markers. According
to laboratory references, procalcitonin values were dichoto-
mized into “non-septic values” (concentrations lower than
2 μg/l) and “septic values” (concentrations greater than
2 μg/l). Analogously, LBP values were dichotomized into
“normal values” (concentrations lower than 10 μg/ml) and
“increased values” (concentrations greater than 10 μg/ml).
Results
Descriptive characteristics of the studied subjects, laborato-
ry results, causes of death, and statistical results are reported
in Tables 1, 2, and 3.
Postmortem serum
In the 12 cases included in the sepsis group, the cause of death
was attributed to multiple organ failure based on the results of
postmortem investigations as well as the exclusion of other
causes of death. Underlying bacterial septic states were pos-
tulated as being at the origin of the multiple organ failures.
Assuming that normal and pathological PCT and LBP
blood levels in living people show similar ranges in postmor-
tem serum from femoral blood, only one individual (case 4)
among the sepsis-related fatalities presented a normal post-
mortem serum PCT value (0.06 μg/l), with an increased
postmortem serum LBP level (15.4 μg/ml). Blood cultures
revealed the presence of multiple Gram-positive- and Gram-
negative bacteria. Histology showed the presence of multiple
foci of polynuclear neutrophils in both lungs. According to
medical records, the patient suffered from pneumonia and had
received antibiotic treatment 5 days prior to death.
Conversely, one individual among the sepsis-related fatali-
ties (case 1) presented a normal postmortem serum LBP value
(6.1 μg/ml), whereas the postmortem serum PCT level was
increased (23.37 μg/l). Increased levels of both postmortem
serum PCTand LBPwere observed in 10 out of 12 septic cases.
Table 2 (continued)
Subject and
postmortem interval
Age Gender Postmortem serum
procalcitonin
Pericardial fluid
procalcitonin
Postmortem
serum LBP
Pericardial
fluid LBP
Main postmortem
investigation findings
30 h
28 36 M 0.06 0.06 12.2 6.1 Drowning
24 h
29 46 M 5.21 7.55 5.0 3.2 Drug intoxication
51 h
30 61 M 8.26 5.51 6.2 9.1 Positional asphyxia
24 h
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In the 30 control cases, postmortem investigations failed to
reveal findings consistent with the existence of underlying
bacterial infections or septic states. Again, assuming that
normal and pathological PCT and LBP blood levels in living
people show similar ranges in postmortem serum from femo-
ral blood, two cases were observed that revealed increased
postmortem serum PCT values and normal LBP concentra-
tions (case 29, drug intoxication, PCT 5.21 μg/l and LBP
5.0 μg/ml; case 30, positional asphyxia, PCT 8.26 μg/l and
LBP 6.2 μg/ml;) and one case of drowning (case 28) showing
a normal postmortem serum PCT value (0.06 μg/l) but an
increased postmortem serum LBP level (12.2 μg/ml).
As expected, postmortem serum PCT levels were higher in
the sepsis group and differed between the two groups, with
only one false-negative case in the sepsis group (which con-
versely showed an increased LBP value) and two false-
positives in the control group (which conversely showed nor-
mal LBP values). However, assuming that there are a number
of noninfectious situations that may result in increased PCT
levels, one might speculate on the possibility that these two
“false positive” septic cases were indeed “true negative” non-
septic cases, as confirmed by normal LBP values.
Similarly, postmortem serum LBP levels were higher in
the sepsis group and differed between the two groups, with
only one false-negative case in the sepsis group (which
conversely showed an increased PCT value) and one false-
positive case in the control group (which conversely showed
a normal PCT value).
None of the control cases showed increases in both
marker values at the same time. PCT determination in post-
mortem serum in both septic and control groups allowed us
to confirm the diagnostic accuracy of this biomarker in
detecting sepsis-related fatalities (sensitivity 91.67 %, spec-
ificity 93.33 %, AUC 0.93). Similarly, LBP determination in
postmortem serum in both studied groups also allowed
septic states (sensitivity 91.67 %, specificity 96.67 %,
AUC 0.96) to be identified.
Increases in both postmortem serum PCT and LBP levels
were only observed in septic cases. Analogously, both normal
PCT and LBP levels were only found in non-septic cases,
thereby suggesting that converging PCT and LBP results rep-
resent a useful tool in confirming the septic nature of a specific
case (sensitivity 83.33 %, specificity 100 %, AUC 0.99).
Pericardial fluid
Assuming that normal and pathological PCT and LBP blood
levels in living people show similar ranges in postmortem
pericardial fluid (concentrations greater than 2 μg/l for PCT
and greater than 10 μg/ml for LBP), pericardial fluid PCT
levels were higher in the sepsis group and differed between
sepsis and control individuals (sensitivity 75.00 %, speci-
ficity 93.33 %, AUC 0.92).
Pathologically increased postmortem serum PCT levels
in the sepsis group in 11 cases were reflected in patholog-
ically increased pericardial fluid PCT levels in nine cases.
Among the control cases, postmortem serum PCT levels
below the detection limit in 28 cases were reflected in
undetectable pericardial fluid levels in the same 28 cases.
These data concur with those of Schrag et al. [1] who
concluded that procalcitonin can be measured in pericardial
fluid and provide useful information for forensic purposes
when postmortem serum is unavailable.
Lastly, the results of the data analysis revealed that peri-
cardial fluid LBP levels were similar in the studied groups.
Postmortem serum and pericardial fluid LBP values in both
septic and non-septic groups were incomparable, as well as
pericardial fluid PCT and LBP levels (sensitivity 16.67 %,
specificity 93.33 %, AUC 0.81), suggesting that the
determination of LBP in pericardial fluid does not ap-
pear to be an alternative option should postmortem
serum be unavailable.
Right cardiac blood
Since neither antemortem blood cultures nor documented
diagnosis of sepsis in vivo were available for the cases
included in the sepsis group, results obtained from microbi-
ology were cautiously interpreted due to the possibility of
postmortem contamination.
Discussion
The aim of this study was to investigate the diagnostic
performance of two biochemical markers, PCT and LBP,
combined or individually considered, to identify sepsis-
Table 3 Summarizes sensitivity,
specificity, and area under the
curve (AUC) for procalcitonin
(PCT) and lipopolysaccharide-
binding protein (LBP) in post-
mortem serum (S) and pericar-
dial fluid (PF)
PCT PCT LBP LBP PCT and LBP
S PF S PF S
Sensitivity 91.67 % 75.00 % 91.67 % 16.67 % 83.33 %
Specificity 93.33 % 93.33 % 96.67 % 93.33 % 100 %
AUC 0.93 0.92 0.96 0.81 0.99
False-positive 2 2 1 2 0
False-negative 1 3 1 10 2
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related fatalities. We furthermore wished to test the useful-
ness of pericardial fluid for LBP determination.
Concerning the first objective, the results of this study
showed that postmortem serum PCT and LBP levels, indi-
vidually considered, allow sepsis cases to be reliably
detected. Additionally, increases in both parameters in post-
mortem serum were observed only in septic cases, suggest-
ing that coherent PCT and LBP results can be used in
forensic routine in order to corroborate the existence of
underlying, bacterial septic states.
Reliable diagnoses of sepsis are of utmost importance in
forensic pathology routine, firstly due to the lack of detailed
medical records when bodies are admitted to the mortuary
for medicolegal investigations, secondly because macro-
scopic and microscopic findings may be elusive or nonspe-
cific. Thus, biochemical markers that could discriminate
between sepsis-related fatalities and noninfectious SIRS
would be of great importance in this field.
Several biochemical markers have been proposed in re-
cent years as potential parameters differentiating between
infectious and noninfectious SIRS in both clinical and fo-
rensic medicine [1–3, 26–32]. The discriminative value of
CRP and interleukin-6 in distinguishing sepsis from nonin-
fectious SIRS is somehow limited due to the fact that both
biomarkers are nonspecific indicators of underlying inflam-
matory processes rather than bacterial sepsis [2, 29].
PCT has been evaluated in multiple clinical settings as a
laboratory tool in differentiating bacterial infections from
other inflammatory states and infectious processes [33, 34].
Four meta-analyses have reported on PCT performance in
the diagnosis of sepsis with conflicting results. Two studies
suggested that PCT is superior to other biochemical param-
eters, whereas two other studies found PCT to have either a
moderate or poor ability in identifying sepsis in critically ill,
adult patients [35–39].
In neonatal sepsis, PCT seems to better discriminate SIRS
from sepsis as well as bacterial infections from non-bacterial
infections in comparison with other biomarkers, though it is
not statistically more accurate than CRP [23, 40]. Adequate
laboratory diagnostics therefore represent a major require-
ment for improving the diagnosis of sepsis [41].
Sepsis is not a single disease but rather a highly hetero-
geneous syndrome that is the final result of host and path-
ogen interactions triggering networks of biochemical
mediators and inflammatory cascades. Clinical expression
is therefore variable and severity is influenced by several
factors including type of pathogen, infection site, clinical
interventions, and host factors, such as genetics and baseline
health [34].
LBP belongs to the acute-phase proteins and is mainly
synthesized by hepatocytes but by epithelial and muscle
cells as well [23, 42]. LBP binds and recruits endotoxin to
the surface of Gram-negative bacteria very early during
infection. Under physiologic circumstances, LBP binds
Gram-negative bacteria via the lipid A part of LPS, which
mediates its binding to the CD14 cellular receptor molecule
presented by monocytes and macrophages. This results in
phagocytosis and clearance of these microorganisms [23,
43]. LBP plasma levels have been investigated in various
human populations: in healthy subjects, LBP plasma con-
centrations range from 2 to 10 μg/ml [44] whereas very high
plasma levels, exceeding 100 μg/ml, have been observed in
patients with sepsis, SIRS, abdominal infections, ulcerative
colitis, and many other diseases. Pavcnik-Arnol et al. [45]
found that LBP was an early marker that differentiated
between noninfectious SIRS and sepsis in critically ill neo-
nates and children with high accuracy. The LBP cutoff value
of >7.4 μg/ml identifying septic syndrome has been
reported for newborns and is nearly identical for adults [46].
In forensic pathology literature, no studies have been per-
formed to compare the discriminative values of LBP and PCT
for the postmortem diagnosis of sepsis-related fatalities.
Reichelt et al. [25] investigated the postmortem behavior of
LPB in two groups of septic and non-septic individuals and
observed a decreasing trend of LBP postmortem serum levels
in both groups with postmortem interval progression. The
authors correlated such decreasing concentrations namely to
the postmortem proteolysis of the molecule with the onset of
significant hemolysis. Based on the results of their investiga-
tions, the authors concluded that LBP postmortem serum
levels above 10 μg/ml could be considered diagnostic clues
for underlying sepsis and proposed at least two measurements
at different postmortem intervals to better estimate the most
probable LBP level at the time of death by using linear
regression analysis. Lastly, they emphasized that in order to
prove underlying sepsis at the time of death beyond any
reasonable doubt, combinations of several biomarkers of sep-
sis should be recommended.
Groselj-Grenc et al. [40] and Pavcnik-Arnol et al. [45,
47] compared the diagnostic accuracy of LBP and other
biochemical markers, including PCT, in differentiating bac-
terial sepsis from non-bacterial SIRS in critically ill neo-
nates and children, concluding that LBP was a better marker
of sepsis than PCT in neonates. The study herein presented
is the first analysis assessing the diagnostic value of LBP
and PCT for the postmortem detection of sepsis as well as
the first study to compare pericardial fluid PCT and LBP
levels.
The results of our investigations indicate high diagnostic
accuracy for both parameters, individually considered and
combined, in detecting sepsis-related outcomes in the post-
mortem period. It is known that LBP levels may increase
after extensive cardiothoracic surgical procedures and de-
crease after death due to the onset of postmortem phenom-
ena [24, 25]. Similarly, numerous non-septic situations can
be characterized by increased PCT values [7, 8, 10–17]. Our
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findings indicate that increases in both postmortem serum
PCT and LBP levels may corroborate the existence of un-
derlying septic states.
Though further studies and investigations are required to
confirm these findings, the results of our data analysis also
indicate that pericardial fluid LBP levels do not correlate with
the presence of increased postmortem serum LBP levels, in
contrast with pericardial fluid PCT levels, which have been
shown to correlate well with postmortem serum values.
No associations were identified between postmortem se-
rum and pericardial fluid LBP levels in either septic or non-
septic groups, nor between pericardial fluid PCT and LBP
levels. Hence, the determination of LBP in pericardial fluid
cannot be considered an alternative to postmortem serum in
situations in which postmortem biochemistry could help in
determining the cause of death and neither peripheral nor
cardiac blood are available upon autopsy.
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